Spruce Biosciences, Inc. (SPRB)
After hours:
| Previous close | 0.4561 |
| Open | 0.4602 |
| Bid | 0.3291 x 200 |
| Ask | 0.5881 x 200 |
| Day's range | 0.4502 - 0.4709 |
| 52-week range | 0.4110 - 5.9500 |
| Volume | |
| Avg. volume | 426,685 |
| Market cap | 18.648M |
| Beta (5Y monthly) | 2.41 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Spruce Biosciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
SOUTH SAN FRANCISCO, Calif., September 03, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024, at 4:30 p.m. ET.
- Business Wire
Spruce Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
SOUTH SAN FRANCISCO, Calif., August 12, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2024 and provided corporate updates.
- Business Wire
Spruce Biosciences Recognized as a Bay Area Best Place to Work
SOUTH SAN FRANCISCO, Calif., June 06, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, announced that the San Francisco Business Times and the Silicon Valley Business Journal have recognized the company as a Best Place to Work in 2024.
